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Abstract
Despite the success of conjugate vaccination against meningococcal group C (MenC) disease, post-vaccination, some
individuals still exhibit rapid waning of initially protective bactericidal antibody levels. The mechanism of this relative loss of
humoral protection remains undetermined. In this report we have investigated the relationship between T- and B-cell
activation and co-stimulation and the loss of protective antibody titers. We have found that healthy volunteers who lose
protective MenC antibody levels one year after receipt of glycoconjugate vaccine exhibit no detectable cellular defect in
polyclonal B- or T-cell activation, proliferation or the B-memory pool. This suggests that the processes underlying the more
rapid loss of antibody levels are independent of defects in either initial T- or B-cell activation.
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Introduction
Since the introduction of meningococcal group C conjugate
(MCC) vaccines, rates of infection have fallen significantly in the
UK [1,2]. However a number of cases of secondary vaccine
failure, in which an initially protective level of antibody wanes over
time leading to vulnerability to infection, still occur [3].
While plain polysaccharide vaccines are able to induce
protective antibody responses via direct stimulation of B-cells by
cross-linking of the B-cell receptor, this stimulus alone does not
induce large scale switching of B-cells to long lived plasma cells or
memory B-cells. For longer lasting immunity, T-cell help is
required [4,5]. In MCC vaccination, peptide (usually CRM197 or
tetanus toxoid) conjugated to polysaccharide is presented to T-cells
via MHC-II on B-cells or other antigen presenting cells along with
co-stimulatory signalling via CD80/86. This triggers T-cell help
and the delivery of cognate signals such as CD40-CD40 ligand
interaction with polysaccharide specific B-cells [6] leading to
differentiation into both antibody producing plasma cells and B-
memory cells [7]. This memory B-cell population is vital for both
immunological memory and longer term antibody production as
memory B-cells are able to renew the population of shorter lived
plasma cells over time [8]. As a result, successful and long lasting
responses to MCC vaccination requires both B-cell recognition of
polysaccharide and effective delivery of T-cell help to those B cells.
We have previously found that waning of protective antibody
levels occurs in a small but significant proportion of subjects
vaccinated with MCC vaccine after one year [9]. To determine
whether the loss of putative protective antibody levels in this
population is related to intrinsic host peripheral blood B- and T-
lymphocyte activity, we have used an in vitro cellular assay that
models the cognate interactions between B and T-cells that occur
following conjugate vaccination. We measured the response of B-
cells to a polyclonal mimic of bacterial capsular polysaccharide,
delivery of T-cell help to B-cells, and T-cell responses themselves.
Using this model we have previously found polyclonal B and T cell
defects in both unvaccinated [10] and previously MCC vaccinated
[11] patients who have suffered meningococcal disease and in
patients who have suffered an episode of invasive pneumococcal
disease [12] suggesting that defects in B and T cell function may
play a common role in susceptibility to infection by encapsulated
bacteria.
In this case we found no evidence of a definable defect in either
polyclonal B-or T-cell activation, proliferation or the existing B-
memory pool, in individuals who have lost protective antibody
levels one year post vaccination. This suggests that the processes
underlying the more rapid loss of protective antibody levels are
independent from defects in initial T- and B-cell activation.
Methods
Study population and clinical procedures
116 undergraduate and postgraduate students (median age 23,
range 19 to 39 years) presenting for meningococcal vaccination
were vaccinated with meningococcal group C polysaccharide
conjugated to tetanus toxoid (NeisVac-C, Baxter). Antibody
responses were measured in serum taken at 0 and 28 days, and
again one year later, as reported previously [9]. In addition a
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activation as described below.
Of the original 116 subjects, 89 returned 1 year later. As
described previously [9] all subjects initially responded to
vaccination but 11 subjects were found to have serum bactericidal
antibody (SBA) levels that had dropped below the threshold of
protection, with rabbit complement derived SBA titers r below 8
(SBA,8) [13,14].
This SBA low group was then compared to age and sex
matched controls who had retained protective SBA levels (SBA
high group) using the cell stimulation assay described below. Since
there is still some uncertainty as to the protected status of
individuals with intermediate SBA titers, equal to or above 8 but
below 128 [14,15] the SBA high group was selected only from
individuals with SBA titers equal to or above 128.
All subjects gave written informed consent and the procedures
were approved by the Central Office for Research Ethics (United
Kingdom, Ref. 04/S0501/34).
Cell stimulation materials
B-cells were stimulated with the TI-II antigen mimic a-h-
dextran (a-h-dex). a-h-dex consists of multivalent anti-IgD
antibodies conjugated to dextran and has been used in a number
of studies as a polyclonal B-cell activator [10,11,16,17,18]. a-h-dex
was made as described previously [19,20]. a-h-dex polyclonally
activates B-cells by cross-linking IgD within the B-cell receptor
complex (BCR).
T-cells were activated by plate-bound anti-CD3 either alone or
with anti-CD28 (both Caltag laboratories). In this system anti-
CD3 mimics T-cell receptor signalling while anti-CD28 mimics
the CD80/86 co-stimulation of T-cell CD28.
Cell isolation and stimulation
Peripheral blood mononuclear cells (PBMCs) were isolated from
fresh heparinised blood by centrifugation with lymphocyte separa-
tion media (Biowhittaker) and removal of the buffy coat before
washing. For proliferation experiments cells were also stained with
2 mM CFSE (Invitrogen). Cells were enumerated by haemocytom-
eter with dead cells excluded on the basis of trypan blue (Sigma)
staining. Cells were added to 48-well plates at a concentration of
2610
6 cells per ml in a final volume of 500 mlR P M I1 6 4 0p l u sL -
glutamine (Gibco) containing 10% autologous plasma.
For analysis of basal CD3 and CD28 expression, and memory
B-cell populations, cells were harvested at day 0.
For analysis of B- and T-cell responses to stimulation, T-cells
were stimulated with 0.1 mg/ml plate-bound anti-CD3 or 0.5 mg/
ml plate-bound anti-CD3 and anti-CD28. B-cell stimulation was
provided by 1 mg/ml a-h-dex both in the presence and absence of
the T-cell stimulators. Except where otherwise noted, cells were
incubated at 37uC, 5% CO2 in a humidified atmosphere for
96 hours before harvesting; supernatants were also collected for
cytokine analysis.
Antibodies and cell staining
For immunofluorescence staining, the following antibody/cell
stains were used in the following combinations. Proliferation and
activation of B- and T-cells was measured by multi-parameter flow
cytometry with the following combination of fluorochromes; Day 0
analysis- IgD PE, CD3 Alexa700, CD4 APC, CD19PE-Cy7,
CD28 Alexa488, CD27 APC-Alexa750 (All Caltag Laboratories).
Activation analysis- CFSE (Invitrogen), CD14 Pacific Blue, CD25
PE, CD86 PE-Alexa700, CD19 PE-Cy7, CD4 APC, CD27 APC-
Alexa750 (all Caltag Laboratories) and UV Live/Dead (Invitro-
gen). Immunofluorescence staining for flow cytometric analysis
was performed by incubating 1610
6 PBMCs with the relevant
antibodies suspended in PBS with 0.1% BSA for 1 hour at 4uC
before washing and fixation with 1% paraformaldehyde.
Flow cytometry
Cells were analysed using a LSRII flow cytometer (BD). T- and B-
cells were identified by a sequential gating strategy in the following
order; Forward versus side scatter (FSC/SSC) gating on lymphocytes,
Doublet discrimination (FSC-Area vs. FSC-Height), live cell discrim-
ination by UV Live/Dead dye, monocyte exclusion by gating on
CD14 negative cells and finally gating on the relevant cell populations
(CD4, CD19). A total of 100,000 events were collected for each
analysis. Compensation was done post-hoc with the compensation
package of FlowJo
TM software (Tree Star) in conjunction with anti-
mouse compensation beads (BD) or cell based staining in the cases of
CFSE and UV Live/Dead. In order to ensure reproducibility,
cytometer setup and tracking was performed using Cytometer setup
and tracking beads (BD) and FACSdiva
TM software (BD).
CFSE proliferation was measured by the use of the FlowJo
proliferation analysis platform to calculate the divisional index
(Mean number of divisions undertaken by each cell). Activation
marker levels were assessed by median fluorescence intensity (MFI)
of the relevant conjugated fluorochromes.
Cytokine measurement
Measurement of cytokines (IL-5, -10, -13, 17, TNF-a, IFN-c
and IL-1b) in collected supernatants was carried out using
Cytometric Bead Array Flexsets (BD) according to manufacturers’
instructions. Results were collected on a BD FACSArray using BD
FACSArray software for acquisition and FCAP array software
(Soft Flow) for analysis.
Statistics
Distribution of results were analysed graphically and by the
D’Agostino-Pearson test to establish if results had a parametric
distribution. The majority of the cellular activation and prolifer-
ation data was found to be normally distributed once transformed
by square rooting. Where data were normally distributed one-way
ANOVA with post-tests were used. In order to reduce the
potential for type-II errors induced by multiplicity corrections we
restricted statistical analysis to relevant comparisons by use of the
Bonferroni selected pairs post-test.
Results
Individuals who have lost protective SBA titer one year
post-vaccination do not have altered T-cell marker or
memory B-cell distribution
To determine if any observed differences in anti-CD3 and anti-
CD28 response were due to differences in CD3 and CD28
expression by CD4
+ cells we analysed the level of surface
expression of these markers. No significant difference was seen
between the SBA low group (SBA titer ,8) and the matched
controls (Figure 1a).
In addition we analysed the relative ratios of memory B-cell
subsets (specifically CD27+ IgD+ memory cells , CD27+ IgD2
isotype-switched memory cells, CD272 IgD+ naive B-cells and
the CD272 IgD2 population comprising of a mixture of CD272
switched memory cells and exhausted memory cells[21,22,23]) to
investigate the possibility that a loss of protective antibody might
be due to a pre-existing defect in memory B-cell generation or
isotype switching. Also since we used anti-IgD based stimulation it
was necessary to ensure that there was no difference in the
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31160Figure 1. T-cell CD3 and CD28 expression and B-cell memory pool distribution. PBMCs were extracted from subjects with a MenC SBA titer
,8 and matched controls one year post vaccination and levels of T-cell CD3 and CD28 expression B-cell memory subsets were examined by
flowcytometry. n=11, One-way ANOVA+ Bonferroni selected pairs post-test (SBA low vs. SBA high).
doi:10.1371/journal.pone.0031160.g001
Figure 2. T-cell and B-cell activation/proliferation in response to polyclonal stimuli. PBMCs were extracted from subjects with a MenC SBA
titer ,8 and from matched controls one year post vaccination and stimulated for 96 hours with plate bound aCD36aCD28 and/or the TI-II antigen
mimic, a-d-dex. Activation and proliferation was measured by expression of A) CD25 Median Fluorescence Intensity (MFI) of CD4
+ cells, B) CD27 MFI of
CD4
+ cells, C) Proliferation of CD4
+ cells, D) CD25 MFI CD19
+ cells, E) CD86 MFI of CD19
+ cells and F) Proliferation of CD19
+ cells. n=11, data square
rooted for normality, One-way ANOVA+ Bonferroni selected pairs post-test (SBA low vs. SBA high).
doi:10.1371/journal.pone.0031160.g002
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found between the low group and SBA high controls (Figure 1b).
Individuals who have lost protective SBA titers one year
post-vaccination do not have a T- or B- cell activation
defect
To investigate the possibility that poor retention of anti-
MenC SBA concentrations may be related to an observable
defect in cellular activation of B- and T-cells we compared the
response to polyclonal stimulation of SBA low donors (at 12
months) to age and sex matched controls with protective SBA
titers. There was a trend towards increased T-cell activation/
proliferation with concurrent lower B-cell activation seen in the
SBA low donors in comparison to the SBA high donors but this
was not statistically significant (Figure 2). In addition to
analysis of the total B-cell population we also examined any
differences in the CD27
+ memory population alone, again we
did not see any significant differences between the SBA low and
Figure 3. Cytokine production in response to polyclonal stimuli. PBMCs were extracted from subjects with an MenC SBA titer ,8 one year
post vaccination and matched controls and stimulated for 96 hours with plate bound aCD36aCD28 and/or the TI-II antigen mimic, a-d-dex.
Supernatants were collected and cytokine concentrations assessed by cytometric bead array. n=10. One-way ANOVA+ Bonferroni selected pairs
post-test (SBA low vs. SBA high).
doi:10.1371/journal.pone.0031160.g003
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expression (Figure S1).
Individuals who have lost protective SBA titers one year
post-vaccination do not have a detectable change in ex-
vivo cytokine production by polyclonally stimulated
lymphocytes
There was no difference between the SBA low and high groups
in the levels of induced cytokines found in the supernatants after
96 hours of stimulation (Figure 3).
Discussion
We did not see a definable difference in the cellular
measurements assessed in this study between the group of donors
who lost protective MenC SBA levels one year post vaccination
and those who did not. This adds further information to our
previous findings that patients who have suffered meningococcal
disease despite vaccination have a definable polyclonal T-cell
defect both in T-cell activation and delivery of T-cell help to B-
cells [11]. The previous study investigated vaccinees who actually
succumbed to disease, rather than those who lost immunological
protection defined by an immunological surrogate of protection,
and are therefore a distinct population to the normal volunteers
studied here. As described by Goldschneider and colleagues the
majority of individuals without a protective SBA level colonised by
meningococci do not develop disease [24]. Thus, an SBA titer
below the protective cut off is necessary, but may not be sufficient,
for susceptibility to disease. Taken together with our previous data
in which we identified a defect in T cell polyclonal activation in
vaccine failures who had succumbed to disease [11], our results
would support this hypothesis. Were the vaccine failures (who
succumbed to disease) from the same population as our SBA low
group (at one year), then the same T cell defect should have been
evident. In the previous study [11] we concluded that the observed
deficiency in T-cell help to B-cells may have been the cause of the
loss of SBA levels due to poor induction of long lasting B-cell
immunity, however in the light of the results presented here it now
seems more likely that the observed deficiency is an additional risk
factor that determines susceptibility to infection in individuals who
have lost protective SBA levels, rather than the cause of the loss of
SBA itself.
In mice at least, the response to whole polysaccharide on whole
encapsulated bacteria is more close to a T-dependent response
than to a T-independent response to polysaccharide alone [25]. It
is possible then that susceptibility to disease depends both on a
level of circulating SBA below the threshold, and on a poor, or
slow (T-dependent) response to whole organisms on colonisation
or perhaps more likely, on invasion.
Since the half-life of antibody producing plasma cells is
estimated to be around 40 days [8] it seems likely that any loss
of antibody protection may be due to poor initial induction of B-
memory cells. However, we did not find any evidence of difference
in either the starting B-memory pool or in of the CD27+ memory
B-cell response to polyclonal stimulation, suggesting that any loss
of antibody protection is not due to an intrinsic imbalance in
memory B-cell production, class switching or an inability of the
cells to respond to stimulation. This may be supported by the
finding that the number and persistence of Men-C specific
memory B-cells induced by MCC vaccination is not age
dependent [26]. Given that the protection offered by MCC
vaccination does vary with age [27] it then seems likely that
variation in memory B-cell populations may not be the critical
factor in determining vaccine efficacy.
As with cellular activation, cytokine levels were not significantly
different between the SBA low and high groups demonstrating no
difference in the Th1, Th2 or Th17 cytokine profiles.
A number of caveats must be attached to these data. First we are
reliant on peripheral blood lymphocytes due to the difficulties in
accessing other immunological compartments in humans. How-
ever, it has been suggested that memory B-cells found in
peripheral blood are representative of the total cell population
[28]. The use of polyclonal stimulation by a-d-dextran and anti-
CD3 is a broad method necessitated by the great difficulty in
detecting changes in the extremely small proportion of circulating
B-or T-cells that would respond to stimulation by a single antigen,
however this methodology has been previously used to successfully
identify immune-defects in several disease contexts [11,12,16].
While we do not rule out the possibility of a more antigen specific
defect being present we are able to conclude that the groups shown
here lack the previously described polyclonal activation defects
that we have identified in several cohorts of meningococcal disease
sufferers [10,11].
The findings presented here suggest that the observed waning of
antibody levels seen in the normal population is not due to any
detectable defect in initial T or B-cell activation. We suggest that
the defects in T-cell activation observed amongst patients who
have experienced disease are an additional risk factor in antibody-
unprotected groups rather than the cause of the loss of antibody.
Supporting Information
Figure S1 Memory and non-memory B-cell activation/
proliferation in response to polyclonal stimuli. PBMCs
were extracted from subjects with a MenC SBA titer ,8 and from
matched controls one year post vaccination and stimulated for
96 hours with plate bound aCD36aCD28 and/or the TI-II
antigen mimic, a-d-dex. Activation and proliferation was mea-
sured by expression of A&D) CD25 MFI of CD19
+ cells, B&E)
CD86 MFI of CD19
+ cells and C&F) Proliferation of CD19
+ cells.
A, B and C) CD27
+ memory B-cells. D, E and F) CD27
2 non-
memory B-cells. n=11, data square rooted for normality, One-
way ANOVA+ Bonferroni selected pairs post-test (SBA low vs.
SBA high).
(TIF)
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